A surgical center administrator explains why the Zimmer Biomet products catalog is only the starting point—contracts, biosensors, patient monitoring systems, and hidden costs matter more.
A quality-focused look at orthopedic and dental implant decisions, surgical technique documentation, sports medicine offerings, and the clinical microbiology behind infection control—written from the perspective of someone who reviews compliance and quality for a living.
A front-line guide for hospital procurement and surgery center managers navigating emergency orders for high-stakes medical equipment like ICU monitors, medical imaging, and laparoscopy sets. Based on real-world pitfalls and industry evolution at Zimmer Biomet.
Answers to common questions about Zimmer Biomet—from what the logo means to what orthopedic implants they supply—written from a procurement perspective.
A practical, step-by-step checklist for hospitals and surgery centers to evaluate orthopedic implant suppliers, written from a quality management perspective.
An admin buyer shares real-world lessons on why opaque pricing and hidden fees in medical device procurement (orthopedic implants, dental implants, robotic surgery systems) end up costing more than the sticker price — and how transparency from vendors like Zimmer Biomet builds long-term trust.
A practical guide to Zimmer Biomet's product lines across orthopedics, dental, and surgical robotics—helping hospitals, surgery centers, and dental clinics choose what fits their specific case mix, budget, and operational setup.
A procurement manager explains why seemingly unrelated medical technologies like electric wheelchairs, defibrillators (AEDs), and nuclear medicine are critical to understanding the full ecosystem of a company like Zimmer Biomet—and why ignoring them is a costly mistake.
As a procurement manager managing a multi-million dollar medical device budget, I walk you through how to evaluate total cost of ownership (TCO) for orthopedic implants, robotic systems, infusion pumps, and hematology analyzers. Three real-world scenarios show why the cheapest quote often isn’t the cheapest in the long run.